Skip to content

Maze Therapeutics, Inc.

Public company
Headquarters
SOUTH SAN FRANCISCO, California
Industry
Biotechnology
Ticker
MAZE
CIK
0001842295

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

6
4 appointments, 2 departures

Last event

Aug 17, 2026
Executive appointmentClass III director appointed: Paula A. Johnson, M.D., M.P.H.

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
Class III directorPaula A. Johnson, M.D., M.P.H.Aug 17, 2026Appointed
Class I directorSophie Kornowski, Pharm.D.Aug 17, 2026Appointed
Class II directorNancy C. Andrews, M.D., Ph.D.Aug 17, 2026Appointed

Related companies

Same industry and state, with recent events.

  1. Executive appointment

    Class III director appointed: Paula A. Johnson, M.D., M.P.H.

    Paula A. Johnson, M.D., M.P.H. was named Class III director of Maze Therapeutics, Inc., effective August 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class III director

    Source: SEC 8-K, filed Aug 17, 2026

  2. Executive appointment

    Class I director appointed: Sophie Kornowski, Pharm.D.

    Sophie Kornowski, Pharm.D. was named Class I director of Maze Therapeutics, Inc., effective August 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class I director

    Source: SEC 8-K, filed Aug 17, 2026

  3. Executive departure

    Class III director departs: Nancy C. Andrews, M.D., Ph.D.

    Nancy C. Andrews, M.D., Ph.D., Class III director of Maze Therapeutics, Inc., resigns the role, effective August 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class III director

    Source: SEC 8-K, filed Aug 17, 2026

  4. Executive appointment

    Class II director appointed: Nancy C. Andrews, M.D., Ph.D.

    Nancy C. Andrews, M.D., Ph.D. was named Class II director of Maze Therapeutics, Inc., effective August 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class II director

    Source: SEC 8-K, filed Aug 17, 2026

  5. Executive departure

    Class II director departs: Hervé Hoppenot

    Hervé Hoppenot, Class II director of Maze Therapeutics, Inc., resigns the role, effective August 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class II director

    Source: SEC 8-K, filed Aug 17, 2026

  6. Executive appointment

    Class III director appointed: Hervé Hoppenot

    Hervé Hoppenot was named Class III director of Maze Therapeutics, Inc., effective August 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class III director

    Source: SEC 8-K, filed Aug 17, 2026

Last verified Nov 8, 2026